Thanks to advances in science and technology, the research-based pharmaceutical industry is entering an exciting new era in medicines development. Research methods are evolving and we have many promising prospects on the horizon – from the possibilities offered by personalised medicines, to the potential offered by harnessing the power of big data. The innovative pharmaceutical industry is driven by, and drives, medical progress. It aims to turn fundamental research into innovative treatments that are widely available and accessible to patients.
Already, the industry has contributed to signifcant improvements in patient well-being. Today’s European citizens can expect to live up to 30 years longer than they did a century ago. Some major steps in biopharmaceutical research, complimented by many smaller steps, have allowed for reductions in mortality, for instance from HIV/AIDS-related causes and a number of cancers. High blood pressure and cardiovascular disease can be controlled with antihypertensive and cholesterol-lowering medicines; knee or hip replacements prevent patients from immobility; and some cancers can be controlled – or even cured – with the help of new targeted treatments.
European citizens can expect not only to live longer, but to live better quality lives. Yet major hurdles remain, including Alzheimer’s, Multiple Sclerosis, many cancers, and orphan diseases.
Table of Contents
THE PHARMACEUTICAL INDUSTRY: A KEY ASSET TO SCIENTIFIC AND MEDICAL PROGRESS
THE PHARMACEUTICAL INDUSTRY: A KEY ASSET TO THE EUROPEAN ECONOMY
PHARMACEUTICAL INDUSTRY RESEARCH AND DEVELOPMENT IN EUROPE
IMPORTANCE OF PHARMACEUTICAL R&D
EMPLOYMENT IN THE PHARMACEUTICAL INDUSTRY
PHARMACEUTICAL MARKET VALUE (at ex–factory prices)
VAT RATES APPLICABLE TO MEDICINES
PHARMACEUTICAL TRADE BALANCE
TOTAL SPENDING (PUBLIC AND PRIVATE) ON HEALTHCARE AS A PERCENTAGE OF GDP AT MARKET PRICES
PAYMENT FOR PHARMACEUTICALS BY COMPULSORY HEALTH INSURANCE SYSTEMS AND NATIONAL HEALTH SERVICES (ambulatory care only)
CAUSES OF DEATH BY MAJOR DISEASE AREAS IN EUROPE (EU–28)